



<http://researchspace.auckland.ac.nz>

ResearchSpace@Auckland

Copyright Statement

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

General copyright and disclaimer

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the [Library Thesis Consent Form](#) and [Deposit Licence](#).

Note : Masters Theses

The digital copy of a masters thesis is as submitted for examination and contains no corrections. The print copy, usually available in the University Library, may contain corrections made by hand, which have been requested by the supervisor.

**EPIGENETIC CHANGES IN
ALZHEIMER'S AND
HUNTINGTON'S DISEASE**

A semi-quantitative analysis of histone changes

Pritika Joytishna Narayan

*A thesis submitted in complete fulfilment of the requirements for the degree of Doctor of
Philosophy in Pharmacology and Clinical Pharmacology, The University of Auckland, 2011.*

ABSTRACT

Histone acetylation is an epigenetic mechanism that plays a critical role in the regulation of gene transcription, DNA damage repair and DNA replication. Histone acetylation homeostasis is maintained by a balance in the activity of histone deacetylases (HDAC) and acetyltransferases. Disruption in their activity can lead to malfunctioning cells, cell death and disease. There is increasing evidence suggesting that deregulation of histone acetylation and consequential effects leading to aberrant gene expression may influence neurodegenerative disease pathogenesis. To date, rodent models of Huntington's disease (HD) or Alzheimer's disease (AD) have generally exhibited evidence for histone hypoacetylation and reduced gene expression in disease pathogenesis. The use of HDAC inhibitors (HDACi) to restore histone acetylation levels and gene expression of down-regulated genes has shown promise in these models but so far not in the clinic. Furthermore the state of histone acetylation in human HD and AD brain has not been previously characterised. This discrepancy and lack of correlation in HDACi based therapeutic outcomes between lab and clinic formed the foundation of this current study.

Initially semi-quantitative image analysis methods were developed to quantify histone changes. These methods were then used to investigate histone changes in the inferior temporal gyrus and hippocampus of AD and the motor cortex, sensory cortex and cingulate gyrus of HD post mortem brains compared to age and sex matched neurologically normal control brains. Results obtained from semi-quantitative image analysis and Western blot analyses collectively demonstrated that histone H4 is markedly increased (independent of changes in total histone protein) in all regions of interest in HD brains compared to controls. Unlike HD however, histone acetylation increases in AD brains were significantly correlated with changes in total histone protein suggesting different mechanisms of epigenetic deregulation at work in these two diseases. These observations from the human brain highlight not only species differences but raise caution for current epigenome based therapeutic strategies and highlight the need for further investigation and characterisation of the human epigenome, in order to fully understand and develop potential epigenetic therapies to prevent and/or alleviate AD and HD pathogenesis.

I dedicate this thesis to 3 people:

To dear little Joseph Frederick O'Carroll (snow drop), who will always remind me of how precious life is.

To my brother, Praneet Ajit Narayan (Nitti), who I miss dearly, but who lives on in our memories and in the principles he taught me to live by.

And to my Grandmother (Aagi), who never had the opportunity to learn how to read or write, but will always be one of the most learned and strong willed women I know.

ACKNOWLEDGEMENTS

I am sincerely grateful to my supervisors Professor Mike Dragunow, Professor Richard Faull and Dr Allan Sheppard, who laid the foundations for this work a long time ago and to my friends and colleagues at the Centre for Brain Research who have been incredibly supportive and helpful during the entire PhD experience. It has been a privilege to work with you, one and all.

Dear Mike, thank you for your infectious joy and integrity - as a scientist but also in all things LIFE. Thank you for your never-ending enthusiasm, expertise, wise counsel and genuine Super 'vision' for each and every one of us in the lab. I will always remember you for your brilliance, for your love for life, people and pets and for your patience and compassion. You have been a great inspiration for me, particularly in my most formative years, as you led me by example and not expectation. Thank you for seeing potential in me and for creating an environment for me to thrive in.

Dear Richard, thank you for your contagious enthusiasm for all things BRAIN and for the care and consideration you put into the wider community, the Centre for Brain Research and into this work also. Your vision for this centre, your humility and your hard work and commitment to creating excellent science and excellent scientists is humbling and admirable.

I am sincerely grateful to the individuals and family members who have bequeathed the brains of their loved ones for this research. Without this incredible resource, this research could not have been performed.

To my dear Dragunow lab-mates (Hannah Gibbons, Jeff Greenwood, Jo Lim, Thomas Park, Amy Smith, Kerhan Woo, Miranda Alderink, Claire Lill, Sheryl Feng, Deidre MacVeigh, Natacha Coppieters and Hector Monzo). Thank you for your camaraderie and friendship, for all you have taught me, for your technical assistance (particularly Hannah, Claire, Jeff and Natacha) and for your laughter (particularly Amy, Deidre and Kerhan), I could not have completed this without your help and assistance. A special thank you to Tom, I sincerely value and appreciate your IT support skills and humour-full friendship and to Marion Blumenstein for invaluable assistance with statistics throughout the duration of this project. I would also like to thank my colleagues in the wider CBR, particularly Dr Doris Thu, Dr Natasha Grimsey, Dr Alissa Nana, Dr Henry Waldvogel, Dr Maurice Curtis, Dr Scott

Graham, Jacqui Ross, Toby Lowe, Jocelyn Bullock and Frances Biggins for your invaluable technical assistance and support.

Dear Cameron McLean, thank you for your patience, your invaluable coaching, your wit and your 'be excellent to everyone' charisma. Thank you for always being there for me as a friend and fellow science geek ☺.

I would like to thank the Seelye Trust, National Research Centre for Growth and Development, the Health Research Council of New Zealand and the Auckland Medical School Postgraduate Students Association for providing funding for this project and for travel to conferences to present key findings.

I am grateful to all of my family and friends who have been a constant support and encouragement to me.

Dear Mum and Dad (Muni and Ajit Narayan), thank you for the deep love you have for each of your children and for always finding joy in our joy, for your generous spirit and for the freedom and opportunities you have given me. To my dear sister, Priya (and Nesh), thank you for standing up for my freedom always, for your consistent encouragement, wise counsel and love. I love and admire you all so much.

To my dear Yash and Koyal, thank you for your love, for being so much fun, for always making me laugh and for being the reason for my greatest joy and affection.

Dear Jenny and Brian Caston, you have both been a great blessing to me, thank you especially to Jenny, my mentor and friend. Your wisdom, your 'can-do' attitude, your faithfulness and your patience will always be treasured. You mean a lot to me and I love you both dearly.

To my Roseman home-mates and Roskill 'neighbours', particularly Brenda Fenton, Natalie Slade, Charlie Kidwell, Rita Oliver, Jade Stanger, Martin Windsor, Naomi Thompson, Rui Peng, Dave Dallaston and Steven Goulstone. Thank you all for your grace, understanding, unconditional love and for making home the fun oasis that it is. A special thank you to my brother Paul Fletcher (Paulo) and sister-in-law Ana Richards, I am so grateful for you both.

Dear Aresh bhaiya and Kusum bhabi, Lockie and Lisa Melrose, Nitika jiji, Helen and Andrew Saunders, Poni Mama and Mami, David and Christine Griffiths, Babbi jiji and Subbi jiji, Barby and Paul Windsor, Navneet bhaiya and Radhi, Maria Lethbridge, Shon Jiji, Deborah Johnstone, Alysha Gover, Marlies Koevoet, Rebecca Turner, Laura Leman, Kat

Lorenz, Esther Deans, The Stirnemanns, and Miriam Bier, thank you all for the many delicious meals you've fed me and for your encouragement along the way.

Dear Anushka Perinpanayagam and Ben Caston, thank you for your friendship. Thank you for the delightful puns and poetry, the music, the food and cups of tea, the laughter, the culture and philosophy, the infinite conversations and for believing in me. Ben, I am humbled by your persistence in listening to my scientific spiels (as if I was truly talking in earnest, be it in another language☺)

To the Children, who bring me many a fresh perspective and joy (Manea, Kushi, Grace, Priya, Prashniel, Shonika, Shreya, Aryan, Divya, Daivik, Anika, Matthew, Becky, Sania, Anandini, Riya, Janu, Hina, and baby Joseph).

My deepest gratitude goes to my saviour and friend, Jesus Christ. His life and love for humanity amaze me and he is my greatest inspiration.

TABLE OF CONTENTS

CHAPTER 1 General Introduction	1
1.....	1
1.1. The epigenome.....	1
1.1.1. DNA methylation.....	2
1.1.2. Histone modifications	4
1.1.3. Micro RNA	8
1.2. Pharmacology of epigenetics	9
1.2.1. HDAC inhibitors	10
1.2.2. DNA methylation modifiers	11
1.3. Evidence for epigenetic deregulation in brain disorders	14
1.3.1. Alzheimer’s disease	15
1.3.2. Huntington’s Disease	29
1.4. Quantifying epigenetic changes.....	43
1.5. Summary	45
1.6. Thesis Aims.....	46
CHAPTER 2 Materials and Methods	49
2.....	49
2.1. Introduction.....	49
2.2. Materials	50
2.3. Methods	52
2.3.1. Cell culture	52

2.3.2. Immunocytochemistry	54
2.3.3. Western blotting	55
2.3.3.1. Protein lysate preparation	55
2.3.3.2. Electrophoresis, transfer and detection	57
2.3.3.3. Optimisation of WB labelling	59
2.4. Human brain tissue	61
2.4.1. Immunohistochemical labelling of post-mortem brain	62
2.4.1.1. Single immunoperoxidase labelling	62
2.4.2. Antigen retrieval.....	63
2.4.2.1. Formic acid	63
2.4.2.2. Hydrochloric acid	64
2.4.3. Antibody optimisation and controls	65
2.4.4. Nissl staining.....	66
2.4.5. Fluorescent labelling of tissue.....	66
2.4.5.1. Thioflavine S labelling of plaques and tangles	67
2.4.5.2. Hoechst nuclei labelling	68
CHAPTER 3 Development of semi-quantitative image analysis methods	69
3.1. Introduction.....	69
3.2. Methods	71
3.2.1. Cell culture and drug treatments	71
3.3. Image acquisition	72
3.3.1. Brightfield microscopy	72
3.3.1.1. Discovery-1 imaging for micro-well plates.....	72
3.3.1.2. Grid-assisted randomised imaging of post-mortem brain sections	72
3.3.2. Fluorescence imaging.....	73

3.3.3. Confocal imaging.....	74
3.4. Image calibration.....	75
3.5. Image analysis	75
3.5.1. Image processing and comparison of different analysis algorithms	75
3.5.2. Determining biologically relevant parameters of interest.....	78
3.5.2.1. Total cell counts	80
3.5.2.2. Intensity parameters.....	82
3.5.2.3. Area measurements.....	85
3.5.3. Analysis of neuropathological hallmarks	87
3.5.3.1. Amyloid plaque load	90
3.5.3.2. Tau load.....	91
3.5.3.3. Mutant huntingtin inclusion load	92
3.5.4. Quantifying co-localisation	93
3.6. Statistical analysis.....	94
3.7. Image analysis can effectively measure changes in histone acetylation.....	95
3.7.1. VPA and TSA are effective HDAC inhibitors in SK-N-SH cells	95
3.7.2. High content analysis of heterogeneity and drug effects.....	97
3.8. Discussion.....	99
3.9. Conclusions.....	105
CHAPTER 4 Altered Histone Modifications in Alzheimer’s Disease	106
4.1. Introduction.....	106
4.2. Anatomical regions of interest and case information	108
4.3. Methods	115
4.3.1. Statistical analysis	116
4.4. Results	117

4.4.1. Elevated histone levels in inferior temporal gyrus of AD brain	117
4.4.1.1. Significant increase in acetylated and total histone levels in AD	120
4.4.2. No significant histone changes in hippocampus of AD cases	124
4.4.3. Histone changes in AD cerebellum	126
4.4.4. Characterisation of neuropathological hallmarks in AD	128
4.4.4.1. Amyloid plaques.....	128
4.4.4.2. Significant negative correlation between total histone H4 levels and amyloid load in control but not AD cases	129
4.4.4.3. Tau load.....	130
4.4.5. Neurofibrillary lesions and histone changes are correlated in post-mortem AD brains.....	132
4.5. Discussion.....	134
4.5.1. Reduced clearance versus overproduction.....	137
4.5.2. A role for histone changes in HD.....	142
4.6. Conclusions.....	143
CHAPTER 5 Increased histone acetylation in Huntington’s Disease	144
5.1. Introduction.....	144
5.2. Methods	147
5.2.1. Anatomical regions of interest and case information	148
5.2.2. Acid treatment	151
5.2.3. Statistical analysis	151
5.3. Results	152
5.3.1. Significant cell loss in motor cortex and cingulate gyrus.....	152
5.3.2. Greater cell loss with earlier age of onset	154

5.3.3. Histone modifications are altered in motor cortex of HD brain, independently of changes in total histone protein levels.	155
5.3.4. Significant correlation between dimethyl histone H3 and CAG repeat length in HD cases.	157
5.3.5. Dimethyl histone H3 levels are significantly influenced by post-mortem delay	158
5.3.6. Western blot validation of histone changes	159
5.3.7. 4M HCl acid treatment alters histone acetylation levels in HD brain.....	160
5.3.8. Increased histone H4 acetylation in cortical layers and white matter tracts of motor/sensory cortices and cingulate gyrus, independent of changes in total histone levels.....	163
5.3.9. Relationships between neuronal cell loss and histone modifications.....	165
5.3.10. Region and size specific distribution of mutant huntingtin inclusions in HD cases	167
5.3.11. Large inclusion load and acetyl histone H4 increase with disease severity, despite significant cell loss.....	171
5.3.12. HD cases grouped by predominant symptom profiles exhibit distinct patterns of cell loss and histone acetylation across different regions of interest.	175
5.3.13. No significant differences in histone changes in cerebellum of HD cases.....	177
5.4. Discussion	178
5.4.1. Evidence for histone hyperacetylation in post-mortem HD brain.....	179
5.4.2. HD severity influenced by genetic and epigenetic factors	181
5.4.3. The role of mutant huntingtin inclusions may be more toxic than protective...	183
5.4.4. The relationship between region-specific atrophy and histone changes and HD symptom phenotype is unclear.....	185
5.4.5. Alternative approaches to acid based antigen retrieval may need to be explored	185
5.4.6. Conclusions	187

CHAPTER 6 Tissue Microarray Analysis of histone changes in different brain diseases ...	188
6.1. Introduction.....	188
6.2. Methods	190
6.2.1. TMA design, production and case information	190
6.2.2. Immunohistochemistry of paraffin embedded sections.	192
6.3. Image acquisition and analysis.....	194
6.3.1. Statistical analysis	196
6.4. Results	196
6.4.1. Total cell numbers were comparable across cases and regions.....	196
6.4.2. TMA image analysis demonstrated histone changes in AD and Epilepsy cases only	198
6.5. Discussion.....	202
6.5.1. Limitations of TMA.....	203
6.5.2. Advantages of TMA coupled with automated image acquisition and analysis ..	204
6.5.3. Alternative antigen retrieval method	204
6.5.4. Histone changes in AD and epilepsy	205
6.5.5. Conclusions	207
CHAPTER 7 General summary and Future directions	208
7.1. Semi-quantitative image analysis	209
7.2. Histone changes in Alzheimer’s disease	210
7.3. Histone changes in Huntington’s disease	212
7.4. Conclusions.....	216
References.....	217
Appendix I: Raw data from semi-quantitative analysis of post-mortem AD, HD and Control cases.....	275

Appendix 2: Optimisation of Chromatin Immunoprecipitation Techniques	284
9.1. Methods	285
9.1.1. Chromatin Immunoprecipitation	285
9.1.2. Primer design, Polymerase chain reaction and detection of products	289
9.2. Results	290
9.3. Discussion	293

LIST OF FIGURES

Figure 1.1 Drugs that can alter epigenetic modifications.....	4
Figure 1.2 Dietary components that can alter epigenetics.	13
Figure 1.3 AD pathology.....	17
Figure 1.4 Amyloid precursor protein (APP) processing.....	19
Figure 1.5 AICD may facilitate increased histone acetylation..	21
Figure 1.6 Extent of atrophy in HD brain.	31
Figure 1.7 Direct and indirect basal ganglia circuitry.	33
Figure 2.1 SK-N-SH cell plating density (cells/well).	54
Figure 2.2 Optimisation of acetyl histone H3 (Upstate) antibody immunolabelling.....	55
Figure 2.3 Optimisation of protein lysis buffer for Western blot.	57
Figure 2.4 Optimisation of antibody blocking buffer.....	60
Figure 2.5 Optimisation of antibody dilution for Westerns..	60
Figure 2.6 Formic acid antigen retrieval improves Tau labelling.....	63
Figure 2.7 Hydrochloric acid treatment improves total histone protein immunolabelling... ..	64
Figure 2.8 Representative images demonstrating specificity of acetyl histone H4 antisera..	65
Figure 2.9 Serial dilution of acetyl histone H4 antibody to optimise labelling specificity.....	66
Figure 3.1 Randomised sampling of regions of interest using the StereoInvestigator	73
Figure 3.2 Comparison of different image analysis algorithms.	76
Figure 3.3 Image processing with MetaMorph TM image analysis software.	78
Figure 3.4 Representative images of analysis and parameter optimisation.	80
Figure 3.5 Graphical presentation of total nuclei parameter.....	81

Figure 3.6 Correlation of automated and manual counting methods.	82
Figure 3.7 Graphical presentation of intensity parameters	84
Figure 3.8 Correlation between qualitative and semi-automated measures of intensity	85
Figure 3.9 Graphical presentation of area measurements.....	87
Figure 3.10 Image processing and segmentation used to analyse amyloid plaque load.....	91
Figure 3.11 Image processing and segmentation used to analyse total Tau load.	92
Figure 3.12 Image processing used to analyse mutant huntingtin inclusion load.	93
Figure 3.13 Co-localisation between acetylated nuclei and different cell types	94
Figure 3.14 Immunolabelling and Western blots of acetyl histone H3 in SK-N-SH cells.....	96
Figure 3.15 Heterogeneity of cellular histone acetylation.	97
Figure 3.16 Frequency distributions of heterogeneity in histone acetylation patterns.	98
Figure 3.17 Histone H3 acetylation increases with HDACi concentration	99
Figure 4.1 Schematic diagram of the major circuitry and anatomy of the hippocampus.....	110
Figure 4.2 Schematic diagram of regions studied in AD brain.....	113
Figure 4.3 Nucleus specific acetyl histone H3 and H4 immunolabelling in AD ITG.....	118
Figure 4.4 Acetyl histone H3 immunolabelling in cortical layers of AD ITG	119
Figure 4.5 Histone changes in ITG from control, AD and HD cases.	120
Figure 4.6 Semi-quantitative analysis of histone changes in AD and HD ITG.....	121
Figure 4.7 Correlations between acetyl and total histone levels in AD cases.....	122
Figure 4.8 Western blot validation of histone antibodies	123
Figure 4.9 Co-localisation of acetylated histone H3 nuclei with different cell markers.	124
Figure 4.10 Histone changes in the hippocampus of AD compared to control cases.	125
Figure 4.11 Semi-quantitative analysis of histone changes in AD hippocampus	126
Figure 4.12 Acetyl and total histone H3 and H4 immunolabelling in AD cerebellum.	127

Figure 4.13 Semi-quantitative analysis of histone changes in cerebellum of AD brains.....	127
Figure 4.14 Immunolabelling of β -Amyloid in cortex of 14 post-mortem AD cases.	128
Figure 4.15 Four neurologically normal control cases exhibit high plaque load.....	129
Figure 4.16 Correlation between plaque load and total histone H4 levels in controls.....	130
Figure 4.17 Immunolabelling of neurofibrillary tangles (tau) in AD ITG.	131
Figure 4.18 No correlation between amyloid plaque and tau load.....	132
Figure 4.19 Tau load correlates with histone changes in AD cases.....	133
Figure 4.20 Acetylated histone H3 nuclei in close vicinity to NFT and amyloid plaques.	134
Figure 5.1 Schematic diagram showing HD regions of interest.....	149
Figure 5.2 Grouped by region, comparison of NeuN immunopositive cell losses	153
Figure 5.3 Grouped by region, comparison of SMI32 immunopositive cell losses	154
Figure 5.4 Age of disease onset correlates with total cell loss.....	155
Figure 5.5 Quantitative analysis of increased histone H3 changes in HD brain.....	156
Figure 5.6 Quantitative analysis of increased histone H4 changes in HD brain.....	157
Figure 5.7 Dimethyl histone H3 levels correlate with CAG repeat number in HD cases.....	158
Figure 5.8 Post-mortem delay correlates with dimethyl histone H3 levels in HD brains.	159
Figure 5.9 Western blot validation of histone changes in HD cases.	160
Figure 5.10 Acid pre-treatment alters histone acetylation patterns in HD brain	161
Figure 5.11 Correlations between 4M HCl treated and untreated sections of AD brain.....	162
Figure 5.12 Histone H4 acetylation levels increased in HD brain.....	164
Figure 5.13 Correlation in pyramidal cell loss and histone H4 acetylation in HD SCTx.	166
Figure 5.14 Correlation between pyramidal cell loss and acetyl histone H4 in HD MCTx.....	167
Figure 5.15 Mutant huntingtin inclusion load varies across brain region, in HD cases.	168
Figure 5.16 Mutant huntingtin inclusions in HD compared to control brains.....	168

Figure 5.17 Correlation between mutant huntingtin inclusions, age of onset and CAG repeat	170
Figure 5.18 Large mutant huntingtin inclusions co-localise with acetylated histone H4.....	171
Figure 5.19 Histone H4 acetylation increases with HD grade severity.....	172
Figure 5.20 Large mutant huntingtin inclusion load increases in a grade dependent manner.	173
Figure 5.21 NeuN- and SMI32-immunopositive cell loss with HD grade.	174
Figure 5.22 NeuN- and SMI32-immunopositive cell loss in HD cases grouped by symptom	176
Figure 5.23 Differential histone acetylation pattern across different HD symptom groups.	177
Figure 5.24 Acetyl and total histone levels are similar between HD and control cerebellum.	177
Figure 5.25 Semi-quantitative analysis of histone changes in HD cerebellum.....	178
Figure 6.1 Image acquisition of labelled TMAII cores with Discovery-1.....	195
Figure 6.2 Image analysis of labelled TMAII cores with MetaMorph™	196
Figure 6.3 Nissl labelling across outer and inner cortical layers of MTG.....	197
Figure 6.4 Semi-quantitative analysis of Nissl staining.....	198
Figure 6.5 Histone H3 acetylation in MTG from different neurodegenerative diseases	199
Figure 6.6 Semi-quantitative analysis of histone H3 acetylation levels in TMAII.....	199
Figure 6.7 Total histone H3 expression in MTG from different neurodegenerative diseases	200
Figure 6.8 Semi-quantitative analysis of total histone H3 protein levels in TMAII	200
Figure 6.9 Histone H4 acetylation in MTG from different neurodegenerative diseases	201
Figure 6.10 Increased in histone H4 acetylation in AD and Epilepsy MTG.....	201

Figure 6.11 Total histone H4 expression in MTG from different neurodegenerative diseases	202
Figure 6.12 Increased total histone H4 levels in MTG of AD cases	202
Figure 9.1 ChIP grade antibodies validation.	291
Figure 9.2 Optimisation of template concentration and annealing temperature.	292
Figure 9.3 Optimisation of ChIP antibody concentration.	293

LIST OF TABLES

Table 2.1 Histone-specific antibodies.....	51
Table 2.2 Cell type and misfolded protein-specific antibodies.	52
Table 2.3 Secondary antibodies and tertiary reagents.....	52
Table 3.1 Details of fluorescent filters and confocal laser excitation and collection ranges..	74
Table 3.2 Image calibration details for different objectives.....	75
Table 3.3 Parameters of interest from images analysed with the count nuclei algorithm.....	79
Table 4.1 Summary of regional differences in pathology in post-mortem AD brain,	112
Table 4.2 Control ITG and hippocampus case information	114
Table 4.3 AD ITG and hippocampus case information	115
Table 4.4 HD ITG case information	115
Table 5.1 Control MCtx, SCTX and CG case information	149
Table 5.2 HD MCtx, SCTX and CG case information.	151
Table 6.1 Arrangement of cores in TMAII recipient block.....	190
Table 6.2 Case information for different neurological and control cases used in TMAII.....	191
Table 8.1 Raw data for all histone and pathology markers investigated in AD ITG	276
Table 8.2 Raw data for all histone markers investigated in AD hippocampus	277
Table 8.3 Raw data for all histone markers investigated in AD cerebellum.....	278
Table 8.4 Raw data for all histone markers investigated in HD cerebellum	278
Table 8.5 Raw data for all histone H4 markers investigated in HD motor cortex.	279
Table 8.6 Raw data for all histone H3 markers investigated in HD motor cortex.....	280

Table 8.7 Raw data for mutant huntingtin inclusions in HD MCtx and stereological estimates for NeuN and SMI32 immunopositive cells counts obtained from Dr Doris Thu	281
Table 8.8 Raw data for all histone markers and mutant huntingtin inclusions investigated in HD SCtx and stereological estimates for NeuN and SMI32 immunopositive cells counts obtained from Dr Doris Thu	282
Table 8.9 Raw data for all histone markers and mutant huntingtin inclusions investigated in the HD CG and stereological estimates for NeuN and SMI32 immunopositive cells counts obtained from Dr Doris Thu	283
Table 9.1 Nucleosomal DNA yields obtained from CHIP.....	288
Table 9.2 PCR cycling conditions for RPL30 verification of gDNA obtained from CHIP.	290

GLOSSARY

3-NP	3-nitropropionic acid
5-Aza	5-aza-2'-deoxycytidine
Ach3	Acetyl histone H4
Ach4	Acetyl histone H3
ACTB	Beta actin
AD	Alzheimer's disease
AICD	APP intracellular domain
AMPA	α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
ANOVA	Analysis of Variance
AP-1	Activating protein-1
APOE	Apolipoprotein E
APP	Amyloid precursor protein
APP-CT	APP C-terminal fragments
ATCC	American type cell culture
A β	β -amyloid
BA	Brodmann's area
BSA	Bovine serum albumin
CA	Cornu ammonis
cAMP	Cyclic adenosine 3', 5'-monophosphate
CBP	Cyclic adenosine 3', 5' -monophosphate (cAMP) response element-binding protein (CREB) binding protein
CERAD	Consortium to Establish a Registry for Alzheimer's Disease
ChIP	Chromatin immunoprecipitation
CN	Caudate nucleus
CREB	cAMP response element-binding protein
CSF	Cerebrospinal fluid
DNMT	DNA methyltransferase
dNTP	Deoxyribonucleotide triphosphate
ERK1/2	Extracellular-signal-regulated kinase 1 and 2
ESET	ERG-associated protein with SET domain
FBS	Foetal bovine serum
GABA	Gamma-aminobutyric acid
gDNA	Genomic DNA
GFAP	Glial fibrillary acidic protein
Gpe	Globus pallidum external segment
Gpi	Globus pallidum internal segment
HAT	Histone acetyl transferase
HCl	Hydrochloric acid
HDAC	Histone deacetylase
HDACi	Histone deacetylase inhibitors
HLA	Human leukocyte antigen
HPLC	High performance liquid chromatography
ICC	Immunocytochemistry
IHC	Immunohistochemistry
ITG	Inferior temporal gyrus
mAb	Monoclonal antibody

MALDI-TOF	Matrix-assisted laser desorption/ionization -Time Of Flight
MAPK	p38 mitogen-activated protein kinase
MBD1-3	Methyl binding protein
MeCP1,2	Methyl CpG binding protein 1,2
miRNA	Mirco RNA
MRI	Magnetic resonance imaging
mRNA	Messenger RNA
MSK1/2	Mitogen- and stress-activated protein kinase 1 and 2
MTHFR	5' 10' methylene tetrahydrofolate reductase
NAD	Nicotinamide adenine dinucleotide
NeuN	Neuronal N
NFT	Neurofibrillary tangles
NMDA	N-Methyl-D-aspartic
NMDAR	NMDA receptor
nt	Nucleotide
pAb	Polyclonal antibody
PANH3	Total histone H3
PANH4	Total histone H4
Pb	Lead
PCR	Polymerase chain reaction
PET	Positron emission tomography
PFA	Paraformaldehyde
PHF	Paired helical filaments
PKC	Protein kinase C
PS	Presenilin
Put	Putamen
PVDF	Polyvinylidene fluoride
RCF	Relative centrifugal force
REST	RE1 silencing transcription factor
RPL30	Ribosomal protein L30
RT	Room temperature
SIRT	Sirtuin
SNc	Substantia nigra pars compacta
SNr	Substantia nigra pars reticulata
STN	Subthalamic nucleus
TBP	Tata binding protein
TMA	Tissue microarray
TSA	Trichostatin A
UTR	Untranslated region
VPA	Valproic acid
WB	Western blot
Zn	Zinc